Cyxone receives Notice of Allowance from the US Patent Office for the protection of Rabeximod compound
Cyxone (publ), a biotech company in autoimmune diseases, is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the US patent application 17/891,462 entitled Rabeximod Compounds. The application covers the protection of salt forms of the compound Rabeximod which is being developed as treatment for moderate to severe rheumatoid arthritis.
The notice of allowance is a formal communication from the patent authority in which it indicates that the patent application has reached the status where it is allowed for issuance as a patent. When issued, the patent will be valid until 2042.
The USPTO examiner concluded the following: “the claimed salt forms of the compound of formula (1), pharmaceutical compositions comprising these forms, and methods of treatment of rheumatoid arthritis comprising administering to a subject an amount of a claimed salt form are novel and unobvious over the prior art.”
”I am very pleased to receive the information from the USPTO. The patent is a particularly important part of our patent portfolio as it will broaden the scope for the Rabeximod compound, and significantly extend the patent lifetime for Rabeximod, well into 2042. We have by this provided a considerable amount of value to our project, our company, and our shareholders. The application process has been very well coordinated by our skilled patent lawyers, and specialists. I am incredibly impressed by their work and the process! Collectively, this is a strong confirmation that our new Rabeximod compound is a novel invention and will be protected in one of the most strategically important markets”, says Carl-Magnus Högerkorp, CEO at Cyxone.
Contact
Carl-Magnus Högerkorp, CEO
Tel: +46 (0)70 781 88 12
Email: carl.hogerkorp@cyxone.com
This information is information that Cyxone AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 18.50 CET on 2 April 2023.
About Cyxone
Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit www.cyxone.com
Tags: